We conducted a prospective, naturalistic study to assess the offer and acceptance of p-tau217 in capable patients with cognitive symptoms and possible Alzheimer's disease (AD). p-tau217 was offered to 170/221 (76.9%) eligible patients, of whom 126 (74.1%) accepted. Competing medical priorities (31.4%) and personal decision (59.1%) were the most frequent causes for not offering or rejecting the study, respectively. As neurologists gained experience using p-tau217, both offering (OR 2.19 CI 95% 1.14-4.19) and acceptance (OR 2.71 CI 95% 1.33-5.53) increased. p-tau217 should be offered by experienced clinicians, after considering patient's comorbidity, psychological, and social circumstances. Clear patient decision is mandatory.
Sánchez‐Soblechero et al. (Tue,) studied this question.